Thrombin

Moxicoumone is an anticoagulant.

5-((1H-Indol-3-yl)methylene)imidazolidine-2,4-dione is an inhibitor of dengue virus NS2B-NS3 protease and thrombin. 5-((1H-Indol-3-yl)methylene)imidazolidine-2,4-dione can be used in the research of infectious diseases.

Napsagatran (Ro 46-6240) hydrate is a potent thrombin inhibitor. Napsagatran hydrate exhibits anticoagulant effects in vitro and in vivo. Napsagatran hydrate can be used in antithrombotic research^[1][2].

Inogatran (H-314-27) is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.

Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a K_i of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC₅₀ ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders.

Flovagatran (TGN 255) sodium is a potent and reversible thrombin inhibitor (K_i: 9 nM). Flovagatran sodium can be used in the research of arterial and venous thrombosis.

Isovanillic acid (3-Hydroxy-4-methoxybenzoic acid) is a phenolic acid isolated from isolated from Scrophularia ningpoensis, with anti-thrombotic activity.

Z-Gly-Gly-Arg-AMC TFA is the TFA salt form of Z-Gly-Gly-Arg-AMC (HY-P0019). Z-Gly-Gly-Arg-AMC TFA is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP) (Ex/Em = 390/480 nm).

Bacithrocin B is a thrombin inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 84 μM, 17 μM, 1.7 μM, and 0.02 μM, respectively.

FXIIa-IN-1-IN-2 (Compound 21) is a Factor XIIa inhibitor (K_i^app: 62.2 nM). FXIIa-IN-1-IN-2 can be used for research of thrombosis.

Propacetamol (hydrochloride) (Standard) is the analytical standard of Propacetamol (hydrochloride). This product is intended for research and analytical applications. Propacetamol hydrochloride is a potent, peptidic inhibitor targeting thrombin and granzyme GZMK. Propacetamol hydrochloride specifically blocks the activities of thrombin and GZMK, thereby inhibiting thrombin-mediated PAR-1 cleavage, as well as downstream inflammatory and procoagulant signaling pathways. Through stabilizing IκB proteins, blocking NF-κB activation and reducing systemic levels of proinflammatory/procoagulant biomarkers, Propacetamol hydrochloride exerts multiple effects including anti-inflammatory, antithrombotic, barrier repair, and inhibition of atherosclerotic plaque progression. Propacetamol hydrochloride binds to platelets without interference from kininogen, effectively limiting acute thrombus growth and reducing eosinophil infiltration and goblet cell hyperplasia in asthma models. Propacetamol hydrochloride is an important tool molecule for investigating the mechanisms of atherosclerosis, asthma and related thromboinflammatory diseases.

Pirmagrel is a thrombin synthetase inhibitor. Pirmagrel has inhibitory effects on thrombin secretion stimulated by lipopolysaccharide (HY-D1056).

LB30057 (CI-1028) is an orally active selective thrombin inhibitor with an IC₅₀ value of 0.38 nM for human thrombin. LB30057 can be used in the study of the thrombus model.

TP508 is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 activates endothelial cells and stem cells to revascularize and regenerate tissues.

Thrombin inhibitor 1 is a potent thrombin inhibitor (K_i=0.66 nM, 2xaPTT=0.43 μM).

Desethyl KBT-3022 is the main active metabolite of the new antiplatelet agent, KBT-3022.